AI-native pharma. Advancing regenerative medicine to market.

Dr. Shammaa is a pioneer scientist in the fields of cell therapy and biologics and holds several patents in the field. He conducted the first successful spinal disc repair using stem cells in Canada.

Dr. Shammaa founded several successful biotechnology companies based on his own research, including Pallianera Pharma and Intellistem Technologies, and led the development of multiple therapeutics to market.

He worked in research at McGill University and in the private sector before completing his residency in family medicine at McGill, and went on to complete a fellowship in Sports Medicine at the University of Toronto. He is a published author and a world-renowned expert in cell therapy and translational medicine.

Launa has over two decades of leadership experience in the life sciences sector. She currently holds the positions of Senior Scientific and Clinical Advisor at Model Medicines, Board Chair at Applied Pharmaceutical Innovation, and Board Member at Edmonton Unlimited.

She previously held the position of Chief Operating Officer at TRIO – Translational Research Oncology. Launa obtained her PhD in Pharmaceutical Sciences (Neurochemistry) from the University of Alberta.

Dr. Murphy graduated from Queen's University with a degree in Life Science in 1988, and from the Queen's School of Medicine in 1990. From 1990 to 1995, he completed his Anaesthesia training at Kingston General Hospital and Queen's University.

Dr. Murphy completed a Fellowship in Paediatric Anaesthesiology at Harvard-affiliated Boston Children's Hospital from 1996 to 1997. He was an Assistant Professor at Queen's University from 1997 until 2002 when he left to practice anesthesiology at Samaritan Medical Center in Watertown, New York. In 2003, he became the Chair of Samaritan's Anesthesiology Department and was instrumental in establishing the hospital's first Pain Clinic.

Dr. Murphy returned to Kingston in 2008 to open KOPI, where he is presently Medical Director and again associated with Queen's University as an assistant professor and resident teacher in interventional chronic pain. He has a special interest in safe opioid prescribing and regenerative medicine, and is passionate about the safe provision of interventional care for patients who suffer from chronic pain.

John Cavan brings more than 20 years of financial management experience across public and private sector companies. Prior to joining Cell Technologies, he was CFO at Hepion Pharmaceutical.

Prior to Hepion, he was a consultant with the Pine Hill Group, where he was instrumental in completing over 10 IPOs and financial transactions including business combinations and strategic transactions. Before that, he served as Chief Accounting Officer at Aegerion Pharmaceuticals Inc., where he was instrumental in the company's initial public offering, through which Aegerion achieved $2 billion market capitalization.

He has also held financial positions within the healthcare industry at AlgoRx Pharmaceuticals Inc. and Alpharma, and served in financial and operational positions at Sony, American Express, International Specialty Products, and Nestlé U.S.A. Mr. Cavan currently serves on the Board of Directors of Vantage Health Systems. He holds a BBA in Accountancy from Iona College and an MBA in Finance from Seton Hall University.

Dr. Foster was most recently CEO of a New Jersey-based biotech company focused on liver disease and fibrosis until his resignation in December 2023. He is currently an Adjunct Professor at the Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, and a Board member of Transcriptome Sciences Inc. and Cell Technologies Inc.

Dr. Foster first began working on drug discovery and development in 1988 and has more than 30 years of pharmaceutical and biotech experience. He founded Isotechnika Pharma Inc. in 1993 and was its Chairman and CEO for approximately 21 years. During his tenure, he discovered voclosporin, an immunosuppressive drug to treat autoimmune diseases. In 2002, Dr. Foster structured a USD $215 million licensing deal — Canada's largest at the time — for voclosporin with Hoffmann-La Roche.

Voclosporin is the first ever FDA-approved oral therapy for lupus nephritis, marketed under the brand name Lupkynis®. Lupkynis® has also been approved by the European Commission, the United Kingdom, Switzerland, and Japan.

Dr. Foster has published approximately 230 papers, abstracts and book chapters. He received the Outstanding Alumnus Award from the Faculty of Pharmacy & Pharmaceutical Sciences (2018), the Distinguished Alumni Award (2022), the Alberta Order of Excellence (2024), and the Order of Canada (2025). He is named as an inventor on more than 200 patents.

Katina is an experienced business-oriented lawyer who provides advisory services on corporate strategy, public markets, corporate governance best practices, transactions, intellectual property, negotiation, privacy, and international markets.

Katina holds a law degree from York University - Osgoode Hall Law School and is licensed to practice law in the province of Ontario. She also holds a Master of Science from the University of Toronto and is a registered patent agent in Canada and the United States. Katina is also a Chartered Director.

Sheona is experienced in providing public company and corporate secretary services, stakeholder relations, and corporate governance and human capital advisory. She currently holds the position of Chief Executive Officer at Limelight Capital Services Inc., Director of Corporate Relations at ARO Consulting Inc., and Partner and Corporate Secretary at Black Spruce Industries Inc.

She previously served as Operations Manager and Securities Paralegal at Bacchus Law Corporation. Sheona holds a Bachelor of Business Administration (BBA) from Capilano University.